[HTML][HTML] Profiling of discrete gynecological cancers reveals novel transcriptional modules and common features shared by other cancer types and embryonic stem …
Studies on individual types of gynecological cancers (GCs), utilizing novel expression
technologies, have revealed specific pathogenetic patterns and gene markers for cervical (CC), …
technologies, have revealed specific pathogenetic patterns and gene markers for cervical (CC), …
Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing
The cyclin-dependent kinase inhibitor p21 WAF1/CIP1 (p21) is a cell-cycle checkpoint effector
and inducer of senescence, regulated by p53. Yet, evidence suggests that p21 could also …
and inducer of senescence, regulated by p53. Yet, evidence suggests that p21 could also …
A new tumor suppressor role for the Notch pathway in bladder cancer
The Notch signaling pathway controls cell fates through interactions between neighboring
cells by positively or negatively affecting the processes of proliferation, differentiation and …
cells by positively or negatively affecting the processes of proliferation, differentiation and …
[PDF][PDF] A deep learning framework for predicting response to therapy in cancer
A major challenge in cancer treatment is predicting clinical response to anti-cancer drugs on
a personalized basis. Using a pharmacogenomics database of 1,001 cancer cell lines, we …
a personalized basis. Using a pharmacogenomics database of 1,001 cancer cell lines, we …
KLF4 is involved in the organization and regulation of pluripotency-associated three-dimensional enhancer networks
DC Di Giammartino, A Kloetgen, A Polyzos, Y Liu… - Nature cell …, 2019 - nature.com
Cell fate transitions are accompanied by global transcriptional, epigenetic and topological
changes driven by transcription factors, as is exemplified by reprogramming somatic cells to …
changes driven by transcription factors, as is exemplified by reprogramming somatic cells to …
The lysine‐specific methyltransferase KMT 2C/MLL 3 regulates DNA repair components in cancer
Genome‐wide studies in tumor cells have indicated that chromatin‐modifying proteins are
commonly mutated in human cancers. The lysine‐specific methyltransferase 2C ( KMT 2C/ …
commonly mutated in human cancers. The lysine‐specific methyltransferase 2C ( KMT 2C/ …
[PDF][PDF] H3K27ac bookmarking promotes rapid post-mitotic activation of the pluripotent stem cell program without impacting 3D chromatin reorganization
B Pelham-Webb, A Polyzos, L Wojenski, A Kloetgen… - Molecular cell, 2021 - cell.com
During self-renewal, cell-type-defining features are drastically perturbed in mitosis and must
be faithfully reestablished upon G1 entry, a process that remains largely elusive. Here, we …
be faithfully reestablished upon G1 entry, a process that remains largely elusive. Here, we …
Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule …
A major challenge in cancer treatment is predicting the clinical response to anti-cancer
drugs on a personalized basis. The success of such a task largely depends on the ability to …
drugs on a personalized basis. The success of such a task largely depends on the ability to …
[PDF][PDF] IFNα impairs autophagic degradation of mtDNA promoting autoreactivity of SLE monocytes in a STING-dependent fashion
K Gkirtzimanaki, E Kabrani, D Nikoleri, A Polyzos… - Cell reports, 2018 - cell.com
Interferon α (IFNα) is a prompt and efficient orchestrator of host defense against nucleic acids
but upon chronicity becomes a potent mediator of autoimmunity. Sustained IFNα signaling …
but upon chronicity becomes a potent mediator of autoimmunity. Sustained IFNα signaling …
Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer
…, M Szabolcs, S Koul, Z Li, A Polyzos… - Journal of the …, 2014 - academic.oup.com
Background Pancreatic ductal adenocarcinoma (PDA) is frequently driven by oncogenic
KRAS(KRAS*) mutations. We developed a mouse model of KRAS*-induced PDA and, based on …
KRAS(KRAS*) mutations. We developed a mouse model of KRAS*-induced PDA and, based on …